Advertisement
Advertisement
INTS
Intensity Therapeutics, Inc. Common stock
4.16
USDSponsored
-0.09
-2.12%
Aug 07, 15:58 UTC -4
Closed
After-Market
4.22
+0.06
+1.44%
INTS Earnings Reports
Positive Surprise Ratio
INTS beat 7 of 12 last estimates.
58%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Intensity Therapeutics, Inc. Common stock earnings per share and revenue
On May 07, 2026, INTS reported earnings of -0.96 USD per share (EPS) for Q1 26, beating the estimate of -1.10 USD, resulting in a 13.26% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.39% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Intensity Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Intensity Therapeutics, Inc. Common stock reported EPS of -$0.96, beating estimates by 13.26%, and revenue of $0.00, 0% as expectations.
How did the market react to Intensity Therapeutics, Inc. Common stock's Q1 2026 earnings?
The stock price moved down -0.39%, changed from $5.11 before the earnings release to $5.09 the day after.
When is Intensity Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Intensity Therapeutics, Inc. Common stock's next earnings report?
Based on --
analysts, Intensity Therapeutics, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement